OMERS ADMINISTRATION Corp Purchases Shares of 19,200 Hims & Hers Health, Inc. $HIMS

OMERS ADMINISTRATION Corp acquired a new position in Hims & Hers Health, Inc. (NYSE:HIMS) during the first quarter, according to its most recent filing with the SEC. The firm acquired 19,200 shares of the company’s stock, valued at approximately $399,000.

A number of other large investors have also recently modified their holdings of the stock. Sigma Planning Corp raised its position in shares of Hims & Hers Health by 1.5% in the 1st quarter. Sigma Planning Corp now owns 26,007 shares of the company’s stock worth $540,000 after acquiring an additional 388 shares in the last quarter. BAM Wealth Management LLC boosted its position in shares of Hims & Hers Health by 5.6% during the fourth quarter. BAM Wealth Management LLC now owns 7,380 shares of the company’s stock valued at $240,000 after purchasing an additional 393 shares in the last quarter. Captrust Financial Advisors grew its stake in Hims & Hers Health by 3.1% in the second quarter. Captrust Financial Advisors now owns 14,612 shares of the company’s stock worth $728,000 after purchasing an additional 443 shares during the period. Binnacle Investments Inc bought a new position in Hims & Hers Health in the third quarter worth $28,000. Finally, Cura Wealth Advisors LLC lifted its position in Hims & Hers Health by 8.5% during the fourth quarter. Cura Wealth Advisors LLC now owns 6,512 shares of the company’s stock valued at $211,000 after buying an additional 512 shares during the period. Institutional investors own 63.52% of the company’s stock.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Patrick Harrison Carroll sold 23,726 shares of the company’s stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $35.00, for a total value of $830,410.00. Following the transaction, the insider owned 181,861 shares in the company, valued at approximately $6,365,135. This represents a 11.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Irene Becklund sold 4,490 shares of the stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total transaction of $141,435.00. Following the sale, the insider owned 6,790 shares in the company, valued at approximately $213,885. The trade was a 39.80% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 83,126 shares of company stock worth $2,711,339 in the last 90 days. Insiders own 11.76% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. JPMorgan Chase & Co. decreased their price target on shares of Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Barclays boosted their price objective on shares of Hims & Hers Health from $29.00 to $39.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 17th. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. Needham & Company LLC raised their target price on shares of Hims & Hers Health from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Finally, Canaccord Genuity Group lifted their target price on shares of Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Four equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and an average price target of $31.43.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: One bullish analysis argues that Hims & Hers remains undervalued, citing projected revenue growth, approximately 73% gross margins, accelerating subscriber additions, GLP-1 and peptide demand, international expansion, and the Novo Nordisk partnership. The thesis suggests substantial long-term upside if the company sustains growth despite the regulatory controversy. Hims & Hers Health: Still an Undervalued Company With Tremendous Upside
• Neutral Sentiment: Several law firms, including SBS Law, Kaplan Fox, Howard G. Smith, and Holzer & Holzer, announced investigations into possible securities-law violations. These announcements are typically investor-solicitation notices and do not establish wrongdoing, but they raise the possibility of shareholder litigation and additional disclosure obligations. SBS Law Investigation
• Negative Sentiment: The FTC alleges Hims & Hers shared customers’ health information with advertising platforms including Meta and Snap, failed to clearly disclose prescription charges, and used potentially deceptive billing and privacy practices. The lawsuit could lead to penalties, higher compliance expenses, tighter restrictions on marketing, and damage to consumer trust. Media coverage of the action contributed to a sharp decline in the shares and remains the principal near-term risk for HIMS. FTC Sues Hims & Hers

Hims & Hers Health Price Performance

Shares of NYSE:HIMS opened at $27.79 on Friday. The business has a fifty day moving average price of $31.23 and a 200-day moving average price of $26.12. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56. The company has a market capitalization of $6.43 billion, a PE ratio of -308.74, a PEG ratio of 76.10 and a beta of 2.35. Hims & Hers Health, Inc. has a 1-year low of $13.74 and a 1-year high of $70.43.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The firm had revenue of $608.10 million during the quarter, compared to the consensus estimate of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The business’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.20 EPS. As a group, equities analysts expect that Hims & Hers Health, Inc. will post 0.03 EPS for the current fiscal year.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.